496MO Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated …
MCR Martinez, JC Castillon, V Alonso… - Annals of …, 2022 - annalsofoncology.org
Background G3 NENs are aggressive tumors with a median overall survival (OS) of∼ 11
months (m) with standard platinum-based front line CT. Their high mutational burden and
PD-L1 overexpression position G3 NENs as potential candidates for immunotherapy. The
aim of this study was to assess the efficacy of the combination of CT plus Nivolumab (Niv) in
patients (pts) with advanced CT-naïve G3 NENs. Methods NICE-NEC is an open-label, non-
randomized, phase II trial that recruited pts with metastatic or locally advanced unresectable …
months (m) with standard platinum-based front line CT. Their high mutational burden and
PD-L1 overexpression position G3 NENs as potential candidates for immunotherapy. The
aim of this study was to assess the efficacy of the combination of CT plus Nivolumab (Niv) in
patients (pts) with advanced CT-naïve G3 NENs. Methods NICE-NEC is an open-label, non-
randomized, phase II trial that recruited pts with metastatic or locally advanced unresectable …
以上显示的是最相近的搜索结果。 查看全部搜索结果